Xin and coworkers [40] provided evidence that more than 50% of EGFR-positive esophageal cancer (EsC) and PM cell lines were resistant to EGFR–tyrosine kinase inhibitors (TKIs). This evidence concerns the gene EGFR and esophageal cancer.